QRxPharma to liquidate assets

By Sarah Danckert - The Australian

In a statement to the Australian Securities Exchange yesterday, QRxPharma said the decision to downsize the company, which employs about 40 staff and consultants, and stop its development of its Moxduo drug, came after US regulators baulked in April at approving its drug. “The management team has since conducted a detailed review of the Moxduo technology with particular emphasis on the EOR meeting with the FDA, and made a recommendation to the board to halt all further development of the Moxduo IR, CR and IV programs,” the company said in a statement. non-essential expenditure and retaining only a core team tasked with exploring all strategic alternatives for the company and its assets.

Read more here: Business Spectator


You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>